9 results about "Drug tolerance" patented technology

The invention belongs to the technical field of biological detection, and particularly relates to a rapid detection method and a micro-fluidic chip for rapid detection. The existing detection method and instrument have the problems of long detection time, incapability of detecting unknown pathogenic bacteria and the like, and cannot meet the timeliness requirement of clinical application. According to the scheme, rapid detection of the drug resistance of bacteria is realized by detecting the growth state of high-throughput single bacteria, and the method comprises the following steps: culturing the bacteria by using the micro-fluidic chip designed in the invention, capturing the single bacteria through a single bacteria capturing channel, and continuously growing in the channel; and obtaining a morphological change matrix of single bacteria evolved along with time in each bacteria capture channel, carrying out statistical analysis to obtain a bacteria phenotype index, and further obtaining the drug tolerance condition of the bacteria on the basis of index numerical value change. According to the method, the function of rapidly detecting the drug resistance of various common clinical pathogenic bacteria within 2 hours can be realized.

This invention discloses a composite nanozyme that enhances the clinical efficacy of oxaliplatin, its preparation method, and its application. The composite nanozyme consists of indium ruthenium nanozyme and an iliximab embedding and anchoring layer. The indium ruthenium nanozyme consists of indium ruthenium nanoparticles and a carbon-nitrogen framework, with the indium ruthenium nanoparticles loaded on the surface and within the pores of the carbon-nitrogen framework. The iliximab embedding and anchoring layer consists of a dithiol polyethylene glycol coating layer and iliximab. Preparation method: ZIF-8 is prepared by co-precipitation of zinc salt methanol solution and 2-methylimidazole methanol solution, followed by calcination to obtain the carbon-nitrogen framework. The carbon-nitrogen framework dispersion is then stirred in an oil bath with indium nitrate solution and ruthenium trichloride solution to prepare a nanozyme precursor, followed by calcination to obtain indium ruthenium nanozyme. The indium ruthenium nanozyme is dispersed in a dithiol polyethylene glycol solution, and iliximab solution is added dropwise. The resulting solid product is then dried. This invention can solve problems such as strong drug tolerance, insufficient intracellular accumulation, and severe tumor immunosuppression in oxaliplatin treatment.

The application discloses a traditional Chinese medicine composition for preventing and treating chicken Bordetella, a preparation method and application thereof. The traditional Chinese medicine composition for preventing and treating chicken Bordetella comprises the following raw medicinal materials in parts by weight: one red 15-20 parts, Tianwen grass 15-20 parts, goldenrod 10-15 parts, Jixiang grass 10-15 parts, white yam 5-12 parts, Buddha's hand 5-12 parts and platycodon 5-10 parts. The traditional Chinese medicine composition adopts one red, Tianwen grass, goldenrod, Jixiang grass, white yam, Buddha's hand and platycodon for reasonable compounding, has the effects of clearing heat and cooling blood, relieving cough and asthma, and can effectively treat chicken Bordetella disease. The seven kinds of medicines are mixed to prepare an oral liquid, the seven kinds of medicines have a synergistic effect in the preparation process, the effects of the medicines are effectively exerted, and the effects of clearing heat and detoxifying, clearing heat and cooling blood, relieving cough and asthma are further enhanced. The composition is scientifically matched, has no obvious toxic side reaction and drug tolerance, and can provide a train of thought for solving the problem of antibiotic resistance.

The application discloses a Toxoplasma SRS29C and ROP16 double-gene deletion strain and a construction method and application thereof, relates to the technical field of parasite genetic engineering and molecular biology. The Toxoplasma SRS29C and ROP16 double-gene deletion strain is obtained by knocking out SRS29C and ROP16 genes of the ME49 strain through a CRISPR / Cas9 system. The double-gene deletion strain constructed by the application has drug sensitivity change (sensitivity to ethidium bromide), growth defect phenotype, and only carries a single screening marker, and under in-vitro culture conditions, the double-gene deletion strain presents a significant slow growth trend, and the number of worm-containing bubbles is obviously less than that of the wild type and single-gene deletion strain. The double-gene deletion strain substantially influences the proliferation of the worm body, and provides key data support for exploring the molecular basis of the double-gene deletion leading to the increase of the drug sensitivity of the worm body and for analyzing the regulation mechanism of the drug tolerance related path of the Toxoplasma.

The invention provides a nerve-soothing and sleep-aiding compound for improving sleep quality and application of the nerve-soothing and sleep-aiding compound. The nerve soothing and sleep aiding compound for improving sleep quality comprises the following components in parts by weight: 10-30 parts of a spina date seed extract, 5-15 parts of a polygala tenuifolia extract, 2-5 parts of sandalwood, 2-3 parts of bergamot, 2-3 parts of corydalis tuber, 1-2 parts of albizia flower, 1-2 parts of chamomile, 2-3 parts of lavender, 3-5 parts of sweet orange and 8-20 parts of a poria cocos extract. According to the nerve-soothing and sleep-aiding compound for improving the sleep quality and the application thereof, the nerve-soothing and sleep-aiding compound adopts various natural plant extracts and functional components, is safe and free of side effects, does not generate drug dependence and drug resistance after being used for a long time, is suitable for being used by people with various sleep disorders, and is free of toxic and side effects. According to the compound, through the synergistic effect of various components, the sleep time can be remarkably shortened, the sleep time can be prolonged, the sleep depth can be improved, the sleep quality can be effectively improved, and the compound has a good improvement effect on sleep disorders caused by pressure, anxiety and the like.

The present invention relates to the technical field of biomedicine, and particularly relates to an HER2-targeting polypeptide-drug conjugate, and a preparation method therefor and the use thereof. The polypeptide-drug conjugate provided in the present invention has good in-situ self-assembly performance in vivo, can bind to HER2 and increase the drug concentration in a tumor area by means of self-assembly at the target site, promotes drug endocytosis, and releases the drug in response to enzyme cleavage in lysosomes, thereby treating tumors having either high or low HER2 expression. In addition, the HER2-targeting polypeptide-drug conjugate provided in the present invention has the property of overcoming HER2 ADC drug tolerance.

According to the invention, the level of the anti-Teprotumumab antibody in human serum is detected by adopting an electrochemical luminescence analysis method. The method comprises the following steps: carrying out pretreatment on a sample in a treatment mode of taking Teprotumumab antibody protein as a capture protein and acidifying and diluting with an acid solution, taking ruthenium-labeled Teprotumumab antibody protein as a detection protein, then carrying out electrochemical luminescence detection, and judging whether the Teprotumumab antibody exists in the sample to be detected according to a light intensity signal value. The method established by the invention has high sensitivity and better drug tolerance, and compared with the existing detection method, the method has obvious technical improvement.

This invention discloses a nucleic acid delivery vector, its preparation method, and its applications, belonging to the field of drug delivery vector technology. The nucleic acid delivery vector provided by this invention is based on the LNP structure, retaining key lipids or lipid-like substances unchanged. By altering the surface composition of the LNP, it can effectively reduce the accumulation of LNP in the liver, achieving effective in-situ mRNA delivery and protein expression; thereby significantly improving LNP organ toxicity, reducing mRNA drug side effects, and enhancing mRNA drug tolerance; it achieves in-situ targeting and high nucleic acid expression by promoting in-situ uptake of the vector and enhancing endosome escape; by optimizing various components and parameters or adding active lipids, the in-situ expression level and stability of the prepared nucleic acid delivery vector can be enhanced; after use, sonication of the application site can also promote the in-situ expression level of the nucleic acid delivery vector.

The application discloses application of rapamycin in preparation of a reliever of opiate drug tolerance caused by an anti-angiogenic drug, the reliever and a medicine, and relates to the technical field of medicine application. It is found that a TSC1-mTOR-autophagy axis plays a role in opiate drug tolerance caused by an anti-angiogenic drug, and the specific embodiment is that the anti-angiogenic drug can cause a decrease in TSC1 content, an mTOR / RPS6 pathway is activated, thereby autophagy flow is blocked, and pain sensation is enhanced; therefore, the opiate tolerance condition can be relieved by adjusting the mTOR / RPS6 pathway through rapamycin.